IFNA1 and neoplasm: In fact, our tMUC1-CAR T cell treatment triggered PD-L1 upregulation on PDAs which was largely dependent on the tumor intrinsic IFN signaling, and HPAFII responded to PD-L1 blocking antibody to show improved CAR T cell killing efficacy.